Skip to main content
. 2020 Jul 19;25(10):e1457–e1463. doi: 10.1634/theoncologist.2020-0610
All Cycles
Name NC/NA 1 2 3 4 5 All grades
Fatigue 36% 52% 12% 0% 0% 0% 64%
Alopecia 44% 48% 8% 0% 0% 0% 56%
Anemia 48% 12% 24% 16% 0% 0% 52%
Nausea 60% 40% 0% 0% 0% 0% 40%
Pharyngeal mucositis 64% 24% 8% 4% 0% 0% 36%
Constipation 72% 28% 0% 0% 0% 0% 28%
Platelet count decreased 72% 16% 12% 0% 0% 0% 28%
Vomiting 72% 28% 0% 0% 0% 0% 28%
Neutrophil count decreased 80% 0% 8% 12% 0% 0% 20%
White blood cell decreased 80% 4% 12% 4% 0% 0% 20%
Somnolence 80% 12% 8% 0% 0% 0% 20%
Diarrhea 84% 12% 0% 4% 0% 0% 16%
General disorders and administration site conditions ‐ Other, specify 84% 16% 0% 0% 0% 0% 16%
Anorexia 88% 12% 0% 0% 0% 0% 12%
Alanine aminotransferase increased 92% 8% 0% 0% 0% 0% 8%
Aspartate aminotransferase increased 96% 4% 0% 0% 0% 0% 4%
Lung infection 92% 0% 0% 8% 0% 0% 8%
Confusion 96% 4% 0% 0% 0% 0% 4%
Gastrointestinal disorders ‐ Other, specify 96% 0% 4% 0% 0% 0% 4%
Generalized muscle weakness 96% 0% 4% 0% 0% 0% 4%
Headache 96% 4% 0% 0% 0% 0% 4%
Hypokalemia 96% 4% 0% 0% 0% 0% 4%
Oral pain 96% 4% 0% 0% 0% 0% 4%
Hallucinations 96% 4% 0% 0% 0% 0% 4%
Skin and subcutaneous tissue disorders ‐ Other, specify 96% 4% 0% 0% 0% 0% 4%
Hypersomnia 96% 0% 4% 0% 0% 0% 4%
Adverse Events Legend
Abbreviation: NC/NA, no change from baseline/no adverse event.